Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment
- Resource Type
- Authors
- Zhangyan Zhou; Shao-Ping Wan; Yongzhi Wang; Dong Chen; Hong Cao; Hai-Hong Zhou; Mou Peng; Quan-Liang Liu; Zhonghua Yang; Xinghuan Wang
- Source
- Asian Journal of Andrology. 13:851-855
- Subject
- Male
medicine.medical_specialty
Urology
Blotting, Western
Enzyme-Linked Immunosorbent Assay
Stimulation
Propranolol
Real-Time Polymerase Chain Reaction
Insulin-like growth factor-binding protein
chemistry.chemical_compound
Erectile Dysfunction
Western blot
Downregulation and upregulation
Internal medicine
medicine
Animals
Rats, Wistar
Cyclic guanosine monophosphate
Antihypertensive Agents
DNA Primers
Base Sequence
biology
medicine.diagnostic_test
business.industry
General Medicine
medicine.disease
Rats
Insulin-Like Growth Factor Binding Protein 3
Endocrinology
Erectile dysfunction
medicine.anatomical_structure
chemistry
Cavernous tissue
Hypertension
biology.protein
Original Article
business
medicine.drug
- Language
- ISSN
- 1745-7262
1008-682X
This study aimed to investigate the role of insulin-like growth factor-binding protein-3 (IGFBP-3) in erectile dysfunction (ED) in two-kidney one-clip (2K–1C) hypertensive rats treated with the β-blocking agent propranolol. Adult male Wistar rats were randomly divided into three groups: a normal control group, a hypertensive control group and a propranolol treatment group (n=9). After 4 weeks of propranolol treatment, intracavernous pressure (ICP) responses to electrical stimulation of the cavernous nerves were evaluated. The expression of IGFBP-3 and insulin-like growth factor-1 (IGF-1) mRNA and protein in the rat cavernous tissue were detected by quantitative real-time PCR and Western blot, respectively. The concentration of cyclic guanosine monophosphate (cGMP) in the cavernous tissue was determined by enzyme-linked immunosorbent assay (ELISA). Cavernosal pressure in response to cavernous nerve stimulation was decreased 4 weeks after propranolol treatment (P